BELIEVE Trial: 92% of Weight Loss From Fat — The Muscle Preservation Breakthrough

The single biggest criticism of GLP-1 medications just got a pharmacological answer. The BELIEVE trial, published in Nature Medicine in March 2026, demonstrated that combining semaglutide with bimagrumab produces 22.1% weight loss where 92.8% comes from fat mass — virtually preserving skeletal muscle.

Trial Design

BELIEVE (NCT05616013) enrolled 507 adults with obesity across nine treatment arms, testing intravenous bimagrumab and subcutaneous semaglutide alone and in combination over 48 weeks with an open-label extension through week 72.

Bimagrumab is a monoclonal antibody targeting type II activin receptors. By blocking activin/myostatin signaling, it promotes muscle growth and fat loss through a completely different pathway than GLP-1 agonism. The combination exploits pharmacological non-redundancy: semaglutide suppresses appetite centrally, while bimagrumab protects muscle peripherally.

The Numbers That Matter

• Combo (bima 30mg/kg + sema 2.4mg): 22.1% weight loss, 92.8% from fat
• Semaglutide 2.4mg alone: 15.7% weight loss, 71.8% from fat
• Bimagrumab alone: 10.8% weight loss, ~100% from fat (actually gained lean mass +2.5%)
• Visceral fat: Combo reduced VAT by 58.2% vs. 35.8% with sema alone
• Total fat mass: Combo reduced by 45.7% vs. 27.8% with sema alone
• Lean mass: Sema alone lost 7.4% lean mass; combo limited loss to 2.9%

Why Men Should Care

For men focused on body composition — not just the number on a scale — BELIEVE represents the proof of concept that we can have dramatic fat loss without sacrificing muscle. The 58.2% visceral fat reduction is particularly relevant for men, who carry disproportionate visceral fat compared to women.

Bimagrumab isn't FDA-approved for obesity yet. Eli Lilly acquired Versanis Bio (the company developing bimagrumab) for $1.9 billion. Studies of bimagrumab + tirzepatide are already underway. This combination framework is likely the next wave of obesity treatment after retatrutide.

What This Means Right Now

You can't get bimagrumab today. But the BELIEVE data reinforces what's already actionable: the muscle-preservation problem is real but solvable. Until pharmacological solutions like bimagrumab reach the market, resistance training + high protein + creatine remain the evidence-based approach. And GLP-1 therapy remains worth starting now — the metabolic and cardiovascular benefits far outweigh the manageable lean mass question.